[Press release – not published yet] Neutralizing antibodies bamlanivimab and etesevimab together reduced risk of COVID-19 hospitalizations and death by 70 percent

New data show treatment with Lilly’s neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent – Lilly

Commentary: Lilly antibody combo therapy cuts risk of COVID-19 deaths – Reuters

Commentary on Twitter

1st Phase 3 trial results on #SARSCoV2 monoclonal antibody combination with very positive results
1035 patients: 11 (2%) v (7%) for death or hospitalization and 0 vs 10 deaths in high-risk patients, given early https://t.co/BXnwCd64O9 (press release).
Coincides w/ EUA criteria. pic.twitter.com/3MjE0XtEqF

— Eric Topol (@EricTopol) January 26, 2021